CCR5 ligands RANTES, macrophage inflammatory protein (MIP)-1a and MIP-1b are potent and specific inhibitors of strains of human immunodeficiency virus (HIV) that use CCR5 as a receptor, which are the strains most involved in primary infection. Recently, we observed that release of CCR5 ligands is a consistent and reproducible parameter of response to antigen activation in studies using PBMC. In this study, we show that CCR5 ligands are released upon antigen [Fragment C of tetanus toxin (TTC)] stimulation in 81% (n 5 16) of subjects tested, as detected by a standard ELISA in tissue culture supernatants of antigen-activated cells. In contrast, ELISA for other cytokines from the same supernatants revealed that IFN-c release could be detected only in 31% of subjects, IL-2 could be detected only in 12% of the subjects and IL-4 was not detectable in any of the subjects tested. Similarly, proliferative responses to TTC, as measured by a standard tritiated thymidine incorporation assay, were detectable in only 56% of the subjects. Similar observations have been reported in flow cytometric studies, and resonate with previous findings emphasizing the role of CCR5 in T cell responses. In addition, the levels of CCR5 ligands in supernatants from antigen-activated cells were sufficient to inhibit infection of R5 HIV. Thus, CCR5 ligands might play a role in controlling HIV in vivo. Taken together, these observations suggest that CCR5 ligands, and in particular MIP-1a and MIP-1b, released in the course of memory responses may play a role in protecting CD4 1 memory T cells from infection.
Introduction
Several surrogate markers have been studied to investigate memory T cell responses. Traditionally, since response to antigenic stimulation triggers a clonal expansion of antigen-specific cells, lymphoproliferative responses have been evaluated, by using assays such as tritiated thymidine ([ 3 H]TdR) uptake. Immune responses are also known to trigger the release of several cytokines, which have also been used as surrogate markers. More recently, the role of chemokines in the elicitation of immune responses has been more thoroughly evaluated [for reviews on this subject, see refs (1, 2) ]. Specific expression of chemokine receptors allows for migration of select cell subsets to sites of antigen presentation. Therefore, while some degree of redundancy exists in the chemokine system, it is possible to ascribe involvement of certain chemokines with components of the immune response (1, 2) . For example, CCR5, which is expressed in monocytes, immature dendritic cells and T h 1 cells, has been involved in memory responses (1, 2) . The ligands for CCR5 are the chemokines RANTES, macrophage inflammatory protein (MIP)-1a and MIP-1b. Interestingly, we had demonstrated that these chemokines are potent and specific inhibitors of certain isolates of human immunodeficiency virus (HIV)-1, i.e. those that infect macrophages and primary cells (3) . Subsequently, it has been shown that this interference is due to the fact that macrophage-tropic isolates of HIV enter cells through CCR5 (4) (5) (6) (7) (8) , hence their current definition as R5 tropic, as opposed to X4, i.e. using CXCR4 (9) , the receptor for the chemokine stromal cell derived factor (SDF-1), or R5X4, for isolates that can use both receptors. Consequently, CCR5 has a dual role, as a receptor for chemokines and as a docking site for HIV infection. Therefore, we became interested in studying the mechanism of CCR5 ligands release in immune response, hypothesizing that their expression in memory responses might provide a novel immunological marker that may participate in controlling HIV infection. To this end, we studied chemokine release in an HIV cohort, stimulating cells from seropositive and seronegative subjects, and from control subjects not enrolled in the cohort. Our study showed that acquired immunodeficiency syndrome (AIDS)-free status and higher CD4 + T cell counts correlate with higher CCR5 ligands release from PBMC after in vitro activation by HIV antigens (10) . These studies are in agreement with published reports from other groups: Furci et al. (11) showed that CD4 + T cells from HIV+ individuals release RANTES, MIP-1a and MIP-1b at levels sufficient to block HIV infection when stimulated with HIV antigens. Ferbas et al. (12) observed a similar antigen-specific response in D32CCR5 heterozygous individuals, whose viral load is inversely correlated with antigen-stimulated chemokine production. While CCR5 ligands are also released from CD8 + T cells in an antigen-specific manner (13, 14) , several studies have shown that CD4 + T cells secrete them at high levels (15) (16) (17) (18) (19) : besides the studies on antigen activation and release of CCR5 ligands quoted above (10) (11) (12) , it has been shown that CD4 + T cells from exposed uninfected individuals release CCR5 ligands (15, 16) , and that CD4 + T cell clones from longterm non-progressing HIV+ subjects release high levels of CCR5 ligands (17, 18) . In addition, a study had shown that CCR5 ligands are part of the vigorous, HIV-1-specific CD4 + response associated with control of HIV viremia (19) . Interestingly, a recent study has shown that, despite the finding that HIV-specific CD4 + memory T cells are the main targets for HIV infection, a significant number of memory cells do not get infected by HIV, even at high multiplicity of infection (20) . There is no evident explanation for this discrepancy, which may be related to the release of anti-viral factors, such as CCR5 ligands, from activated cells. Thus, we wanted to investigate whether the frequency of cognate cells to a recall antigen is high enough to induce levels of CCR5 ligands sufficient to inhibit HIV replication, and whether the accumulation of suppressive levels of CCR5 ligands occurs in a time frame compatible with fusion/entry events [i.e. within 2 h of virus/cell or cell/cell contact (21, 22) ]. To this end, we evaluated the release of CCR5 ligands from PBMC in response to a classic recall antigen, Fragment C of tetanus toxin (TTC). We observed that CCR5 ligands are promptly released upon TTC activation, and that their release, as measured by ELISA, constitutes a marker of memory response more sensitive than IFN-c, IL-2 or IL-4 release, or than lymphoproliferation (as measured by thymidine incorporation). This prompt release appears to be due to pre-existing accumulation of CCR5 ligands. Finally, levels of CCR5 ligands released upon antigenic stimulation are sufficient to inhibit replication of R5 HIV, suggesting that antigen-stimulated cells can contribute to protection against HIV infection.
Methods

Cells and laboratory studies
Fresh PBMC were obtained by Hystopaque separation from whole blood of healthy donors, following the instructions of the manufacturer (Sigma Chemical Co., St Louis, MO, USA). All the donors signed informed consent forms approved by the Institutional Review Board. The lymphocyte proliferation assay was modified from ACTG protocol 209 (10 All b-chemokine assays were performed by commercial ELISA (R&D Systems, Minneapolis, MN, USA). In some experiments, 5 lg ml ÿ1 actinomycin D (Sigma), 2.5 lg ml ÿ1 cycloheximide (Calbiochem) or 5 lg ml ÿ1 brefeldin A (BFA, Sigma) was added to cell culture media for up to 6 h.
Flow cytometry
Whole-blood samples collected from healthy donors were activated with 10 lg ml ÿ1 of TTC (Calbiochem) or Staphylococcus aureus enterotoxin B (SEB; Sigma) at 37°C for 1 h as previously described (23) . Then, the blood sample was treated with BFA (10 lg ml ÿ1 , Sigma) for an additional 5 h. After 6 h, 100 ll of 20 mM EDTA (for a final concentration of 2 mM EDTA) was added directly to the whole-blood cultures. Blood samples were lysed and fixed in 14 ml of 13 FACS lysing solution (BD, San Jose, CA, USA) for 10 min at room temperature (RT). Cells were washed in wash buffer, PBS with 2% heat-inactivated human serum from AB donors and 0.1% sodium azide (Sigma), and subsequently re-suspended in 0.5 ml of FACS permeabilizing solution (BD) for 10 min at RT. After permeabilization, cells were washed once again and stained with fluoresceinconjugated antibodies specific for MIP-1b (R&D Systems), CD3 [BD; labeled with peridinin-chlorophyll protein (PerCP)], CD69 (BD; labeled with PE), IFN-c (BD; labeled with PE) or CD4 [BD; labeled with allophycocyanin (APC)] for 30 min at RT in the dark. Finally, labeled cells were washed two times with wash buffer, fixed with 1% PFA (Fisher, Fair Lawn, NJ, USA) and stored at 4°C. Four-color flow cytometric analysis was preformed by using a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA). Data analysis was carried out using the flowjo software (Tree Star, San Carlos, CA, USA).
Infectivity assay
PHA-activated PBMC (1 3 10 5 PBMC per well) were infected for 2 h with 100 50% tissue culture infective dose (TCID 50 ) of HIV BaL stock of HIV-1 BaL , an R5 isolate. After 2 h, cells were washed three times with PBS and complete media added with 25 or 50% of supernatants from cells activated with TTC or PHA. As controls, we used supernatants from cells that had not been activated, and we infected PBMC without treatment with supernatants from antigen activation. We tested supernatants obtained from cells from different donors and harvested at 8 or 24 h after activation. In some cases, we tested the supernatants in the presence or absence of a cocktail of neutralizing polyclonal IgG (Nab) against CCR5 ligands [100 lg ml ÿ1 each of anti-RANTES, anti-MIP-1a and anti-MIP-1b (R&D Systems)].
Statistical analysis
Analyses of data distribution and of statistical significance using paired two-tailed t-tests were performed using GraphPad InStat, version 3.00, for Windows 95 (GraphPad Software, San Diego, CA, USA).
Results
Antigen-induced chemokine release and proliferation
Our data obtained with antigen stimulation using HIV antigens and C. albicans show that these antigens induce measurable production of CCR5 chemokines (10) . Thus, it appeared that memory responses could trigger CCR5 ligands release. To investigate this hypothesis, we measured chemokine release response to a classical recall antigen, i.e. TTC. We obtained freshly harvested PBMC from healthy volunteers vaccinated against tetanus and cultured them in media without stimulation or activated with TTC (at concentrations of 3, 10 and 20 lg ml ÿ1 ). Positive controls included C. albicans and PHA at 10 lg and 2.5 lg ml ÿ1 , respectively. The cultures were incubated for up to 9 days at 37°C/5% CO 2 . At days 3, 6 and 9, an aliquot of cells was used for a proliferation assay by [ 3 H]TdR uptake, while supernatants were used for RANTES, MIP-1a and MIP-1b assays by ELISA. Our results show that as little as 3 lg ml ÿ1 of Fragment C induces significant MIP-1a and MIP-1b production as early as 3 days post-stimulation (Fig. 1A) . RANTES was present at concentrations higher than MIP-1a and MIP-1b in unstimulated cells, and antigen stimulation did not increase its release as much as that of MIP-1a and MIP-1b (Fig. 1A) . The magnitude of the response was comparable to that to C. albicans antigen (Fig. 1 ). All the subjects who displayed proliferative responses (9 out of 12) also produced chemokines MIP-1a and MIP-1b in response to Fragment C. A positive response was defined as a quantity of chemokine at least four standard deviations above the median of the levels measured in unstimulated cultures. Our data show that while chemokine release can be measured reliably at day 3 post-stimulation, proliferative responses are not measurable at that time point (Fig. 1A and B) , except when the polyclonal stimulator PHA is used (data not shown). Therefore, recall antigen stimulation can be easily measured by chemokine release at time points where little or no cell proliferation is detectable. Importantly, not all chemokines are induced by antigen stimulation. We tested the same supernatants by ELISA for the presence of two other CC chemokines, macrophagederived chemokine (MDC) and I309. Our results indicate that MDC production is significantly delayed as compared with the production of CCR5 ligands, as MDC is barely detectable on day 3, while its concentration rises on day 6 and, more robustly on day 9 (Fig. 2) . In contrast, we could not observe significant increase of I309 production by any stimulus, including PHA (Fig. 2) . Therefore, CCR5 ligands release is detectable at time points when little or no proliferation is detectable.
Kinetics of release of CCR5 ligands
We evaluated the kinetics of release of CCR5 ligands, and found that MIP-1a and MIP-1b are released very early upon antigen activation. A first set of experiments (Fig. 3A) revealed that these chemokines were released as early as 1 day after activation. When we evaluated the production of CCR5 ligand within 1 day of stimulation, we found that MIP-1a and MIP-1b production can be detected as early as 2 h after TTC stimulation, becomes very prominent at 4-6 h and peaks by 16-20 h (Fig. 3B and C) . This suggests that chemokine release is a very early event in the consequence of stimulation by recall antigens.
Production of other cytokines
Since our observation on CCR5 ligands release suggests that these chemokines may be a very sensitive marker of antigen 6 for each activation group) were obtained from healthy donors and stimulated with antigen indicated as described in Methods. Chemokines were detected by a commercial ELISA. [ activation, we investigated the release of cytokines that have classically been linked to immune response, namely, IL-2, IL-4 and IFN-c. We could not detect significant release of IL-4 in response to antigen (TTC and C. albicans) activation (data not shown) by ELISA, at the same dilution factor (1/5) as in the case of CCR5 ligands assays. We were able to detect the release of IFN-c in five (31.2%) out of the 16 donors described above and IL-2 in two (12.5%) of the 16 donors (data not shown) in response to TTC activation. This is in contrast with detectable levels of CCR5 ligands observed in 13 (81.2%) of the same 16 donors. In comparison, when we stimulated cells with C. albicans we detected the release of IFN-c in seven of the 16 donors, while MIP-1a and MIP-1b release was detected in 14 (87.5%) of the 16 donors (IL-2 release was not detectable in any donor with this stimulus).
Chemokine release as a function of time from vaccination
We wanted to establish whether the responses that we observed diminish in magnitude with time from vaccination. We analyzed chemokine production and proliferation (3, 6 and 9 days after stimulation) in four subjects who had not received a tetanus booster in the past 10 years. All these subjects responded to activation by producing chemokines (Fig. 4) . By contrast, antigen-specific proliferation was not detectable at any of the time points tested for any of these volunteers (Fig. 4, data not shown) . Therefore, it appears that chemokine secretion is a more reliable indicator of long-term memory to TTC than T cell proliferation.
Antigen-induced chemokine release can be measured in cryopreserved samples
The results presented above were obtained using freshly harvested PBMC. Since sometimes freshly obtained samples are not available for studies, it was important to determine whether our assay is effective when cryopreserved specimens are used. This was determined using PBMC from healthy donors (N = 12). One aliquot of cells was evaluated for chemokine secretion as described above, while another aliquot was cryopreserved in liquid nitrogen for 4 months. At this time the cells were thawed and stimulated with 3, 10 or 20 lg of TTC, and with C. albicans as control. Cultures were established with media only to provide a negative control. Aliquots of supernatants were harvested at days 3, 6 and 9, and tested for MIP-1a and MIP-1b release by ELISA. On the same days, proliferation was measured by [ 3 H]TdR uptake. Proliferative responses to antigen stimulation could be measured on day 6 in fresh but not cryopreserved cells (data not shown). MIP-1a, but not MIP-1b (Fig. 5) , release was significantly elevated upon TTC stimulation over control values in both fresh and cryopreserved samples. Release of both MIP-1a and MIP-1b was significantly increased upon C. albicans stimulation. RANTES production was also increased. We observed a higher background production and variability of antigen-induced chemokine release in cryopreserved samples compared with freshly obtained cells; nonetheless, we show that MIP-1a can be reliably measured in cryopreserved samples, thus enabling its study in samples obtained from repositories.
Release of CCR5 ligands in the presence of transcription, translation and Golgi apparatus inhibitors
In order to gain some insight into the mechanism of the prompt release of CCR5 ligands, we performed activation experiments with TTC, alone or in the presence of inhibitors of transcription (actinomycin D, 5 lg ml ÿ1 , which inhibits both DNA and DNA polymerization; with short-term treatment it can be assumed that its action is directed mostly against RNA polymerases), translation inhibitors (cycloheximide, 2.5 lg ml ÿ1 ) or posttranslational processing inhibitors (BFA, 5 lg ml ÿ1 , a blocker of transport from endoplasmic reticulum to Golgi apparatus). These studies showed that the early release (2-6 h) of CCR5 ligands MIP-1a (Fig. 6A ) and MIP-1b (Fig. 6B) is dramatically inhibited by BFA, while treatment with transcriptional and translational inhibitors inhibited the release of these chemokines to a much lesser extent, especially at the earlier time points. This suggests that the earlier phases of release of CCR5 ligands are due to a pre-existing intracellular accumulation of the proteins, while transcription and translation contribute at a later time to the production of these chemokines.
Flow cytometric analysis of cells releasing the CCR5 ligand MIP-1b
We investigated the cell types involved in the antigen activation protocol that we used in this study. We have set up a protocol for intracellular staining with MIP-1b antibodies (see Methods) (23) . After stimulation for 6 h with TTC and SEB and blockade of Golgi processing with BFA for 5 h, we stained cells with fluorescein-conjugated antibodies specific for MIP1b, in conjunction with other markers including CD3 (labeled with PerCP), CD4 (labeled with APC), IFN-c (labeled with PE) or CD69 (labeled with PE). Gates were imposed to define lymphocyte population based on cell size and expression of CD3 and CD4. Our analyses indicate that following TTC activation, both CD4 + and CD4 ÿ T cells (putatively ascribed as CD8 + T cells) displayed augmented intracellular staining for MIP-1b, as compared with unstimulated control cells (Fig. 7 -cells in the right quadrant were considered positive). On the contrary, as described previously, in SEB-treated cells, the CD4
ÿ sub-population showed the most dramatic increase in MIP-1b intracellular staining (23). We did not observe a clear-cut association between IFN-c and MIP-1b secretion, or between MIP-1b and the activation marker CD69 (Fig. 7) .
CCR5 ligands in supernatants from antigen-activated cells inhibit infection by R5 tropic HIV-1 in vitro
In order to test whether CCR5 ligands released upon antigen activation of PBMC with recall antigens could inhibit HIV 6 for each activation group) were obtained from 12 healthy donors. An aliquot of the cells used in Fig. 1 were cryopreserved in liquid nitrogen for 4 months, and then thawed and stimulated. Cryopreserved cells were stimulated with 3, 10 or 20 lg of TTC, or cultured with media only, as a control. Aliquots of supernatants were harvested at days 3, 6 and 9, and tested for MIP-1a and MIP-1b release by ELISA. Bars indicate standard error of the mean.
replication, we set up an in vitro infectivity assay using PHAactivated PBMC (1 3 10 5 cells per well), which were infected for 2 h with 100 TCID 50 of HIV BaL , an R5 isolate, and then washed three times and complete media added (25 and 50% of supernatants from cells activated with TTC). As a control, we also used supernatants from cells that had not been activated, and we also infected PBMC without treatment with supernatants from antigen activation. We tested supernatants obtained from cells from five different donors and harvested at 8 or 24 h after activation. In some cases, we tested the supernatants in the presence or absence of a cocktail of neutralizing polyclonal IgG (Nab) against CCR5 ligands (100 lg ml ÿ1 each of anti-RANTES, anti-MIP-1a and anti-MIP-1b, R&D Systems). We observed that supernatants from antigen-activated cells, at both 25% (Fig. 8 ) and 50% (data not shown) concentrations, reproducibly inhibited HIV BaL replication, as measured by the release of p24 in the tissue culture supernatants between days 4 and 10 after infection (Fig. 8) . Interestingly, supernatants from unstimulated cells could also inhibit HIV replication, possibly due to background release of CCR5 ligands, especially RANTES, but the inhibition was lower than that observed using supernatants from activated cells. However, when supernatants were pre-treated for 1 h with Nab to CCR5 ligands prior to being added to the infectivity assays, we observed a complete reversal of the inhibition of HIV replication (Fig. 8) , which suggests that all the inhibitory activity that we observed in this system was due to CCR5 ligands release.
Discussion
Chemokines, by virtue of their ability to attract discrete leukocyte sub-populations, are key mediators of immune response. Their concerted release is the basis of migration of ). Chemokine production in tissue culture supernatants was measured by ELISA at 2 and 6 h after stimulation. cells from the periphery to a site of inflammation or infection (24) . In this study, we investigated the relevance of CCR5 ligands in the context of the immune response triggered by a protein antigen, i.e. TTC. We selected these chemokines since they bind to the HIV co-receptor most involved in primary HIV infection, as demonstrated by the protection from HIV infection conferred by the D32CCR5 mutant allele in the homozygous state (25) (26) (27) (28) (29) (30) . We (10, 31) and others (11, 12, (15) (16) (17) (18) (19) (32) (33) (34) (35) had previously shown that high levels of chemokine release from antigen-activated cells are associated with protection from HIV-1 infection in high-risk subjects, and with better disease outcome in HIV-infected individuals. Furthermore, studies on non-human primates that were immunized against SIV showed that protection was related to high levels of CCR5 release from cells (36) (37) (38) (39) (40) . These findings were consistent with our hypothesis (41) that release of high levels of chemokines may constitute a correlate of protection from viruses that use CCR5 as a receptor to enter target cells (4) (5) (6) (7) (8) , i.e. HIV and simian immunodeficiency virus (SIV). Several studies have shown that CCR5 ligands are released in the course of immune response to a cognate antigen (10-14, 19, 34, 36, 37) . This is of great importance from the viewpoint of developing effective AIDS vaccines, as release of HIV inhibitory chemokines would add an additional line of defense to the classical two arms of the immune response, i.e. neutralizing antibodies and CTL. Therefore, to study the release of CCR5 ligands from blood cells, we chose to study the immune response to an antigen that is the functional equivalent of a subunit vaccine, i.e. TTC, reasoning that an effective HIV vaccine should be at least as capable of triggering an immune response as this experimental antigen. Our results showed that CCR5 ligands release occurs promptly after antigen stimulation, as significant levels of these chemokines, except RANTES, which was measured in supernatants even without simulation, were reached as early as 2 h after activation, and started peaking at around 8 h. The release of MIP-1a and MIP-1b was detectable well before proliferative responses, as measured by uptake of [ 3 H]TdR, which requires 6 days of incubation. Such fast kinetics of release occur in the same time frame as the events required for HIV entry (21) (22) , therefore enabling CCR5 ligands, in principle, to interfere with HIV infection. The fast kinetics of response to antigen suggests that it could be advantageous to measure CCR5 ligands, as compared with measuring lymphocyte proliferation, when responses to vaccines are measured in developing countries, by reducing the amount of equipment required for testing and the time needed for incubation and by eliminating the need for radioactivity. Furthermore, release of CCR5 ligands was found to be a more sensitive marker of immune response to recall antigen than cell proliferation measured by thymidine incorporation, since cells obtained from individuals that had been immunized against tetanus > 10 years prior to testing did not display any detectable proliferative responses to TTC stimulation, while CCR5 ligands release was consistently found to be elevated. Interestingly, we observed that CCR5 ligands were released in a specific manner in response to antigen stimulation, since other chemokines, which also inhibit HIV (42, 43) , were not elevated, as in the case of I309, or were released much later in time, like MDC (Fig. 2) . Flow cytometric analysis of cells secreting MIP-1b revealed that both CD4 + and CD8 + T lymphocytes are involved in the release of this CCR5 ligand in response to TTC. We observed that the percentage of cells that release MIP-1b is comparable to the percentage of cells producing IFN-c, under our experimental conditions. Similar findings were reported by us and others (23, 44) using different stimuli and/or selected cell populations. Thus, it appears that even in flow cytometric analyses, MIP-1b is a marker at least as powerful as IFN-c in detecting cell activation by antigen stimulation. When we analyzed the mechanism of release of CCR5 ligands, we observed that the early phase of release can be inhibited by BFA, which interferes with the processing of proteins in the Golgi apparatus, while inhibitors of transcription and translation had limited efficacy in blocking early CCR5 release. Thus, it appears that the initial release of CCR5 ligands occurs independently of transcription and translation, and is therefore likely to be due to the release of these chemokines from a pre-existing accumulation, which could explain the fast kinetics of this phenomenon. Recent data on memory and effector CD8 + T cells support this concept, having demonstrated that RANTES release occurs in a quick burst within an hour following antigen activation (45, 46) . RANTES production in these conditions appears to be due to a pre-existing accumulation of the protein in the cytoplasm, unlike the release of IFN-c, which occurs later and is probably due to a transcriptional mechanism (46) . The kinetics of RANTES release and its resistance to cycloheximide treatment (47) are very similar to our observations, thus supporting the finding that CCR5 ligands are released as a very early response to antigen activation.
We determined that supernatants from antigen-activated cells could inhibit infection by an R5 isolate of HIV-1. This inhibition was reversed by the addition of anti-CCR5 ligands antibodies, indicating that the bulk of the specific anti-R5 HIV Fig. 8 . Supernatants from antigen-activated cells inhibit R5 HIV replication. Supernatants from PBMC after 8 h of activation were added to 1 3 10 5 cells that were infected for 2 h with 100 TCID 50 of HIV BaL . Some of the supernatants were added with 100 lg each of antibodies against RANTES, MIP-1a and MIP-1b, or with an irrelevant IgG. Cells were then washed three times with PBS, and incubated in the presence of supernatants for up to 10 days. HIV replication was monitored by p24 ELISA. Shown are results from a representative experiment out of five independent experiments performed using supernatants obtained from different donors. activity in these supernatants is due to these chemokines in accordance with our previous studies (10, 31) . Since CCR5 ligands can attract CD4 + T cells, it is conceivable that their release upon antigen activation may contribute to, rather than inhibiting, infection of cells (47) (48) (49) . However, the vast majority of clinical studies suggests that the balance between protection from infection and increased availability of uninfected cells, if existing, is tilted toward protection (10-13, 15-19, 31-35) . It should be noted that most of the literature suggesting that chemokines might be a promoting factor in HIV infection were performed using plasma and serum samples (50) (51) (52) (53) (54) (55) (56) , which yield inherently inaccurate chemokine measurements, vis-à -vis the non-circulating nature of these molecules and their variable levels in these fluids due to the chemokines ability to aggregate and their release from platelets (57) (58) (59) (60) (61) . Thus, in the case of immunization against HIV, it is conceivable that the release of CCR5 ligands could play a role in protection. While it is true that vaccination against pathogens other than HIV has been associated with temporary increases in viremia in HIV-infected subjects (62), a different scenario might occur with HIV immunization. In our hypothetical model, we envision that HIV, which preferentially infects HIV-specific cells (20) , would stimulate a memory response, in individuals immunized against it, which in its early phase would include CCR5 ligands release. This release would prevent HIV entry into target cells, since most primary transmission occurs through R5 strains. Therefore, the overall effect of immune stimulation and CCR5 ligands release should be evaluated in the context of HIV immunization. In support of this hypothesis, several published studies have linked protection from SIV infection to levels of CCR5 ligands in an immunization animal model (36) (37) (38) (39) (40) . Thus, further studies on the release of CCR5 ligands in the context of HIV vaccination are warranted.
In summary, our data show that CCR5 ligands MIP-1a and MIP-1b constitute one of the most sensitive markers of memory response, and are released in quantities and kinetics compatible with inhibition of HIV infection in vitro. Consequently, their study is inescapable in the context of vaccination, toward the goal of identifying immunogens that can protect against HIV infection. 
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